速递｜完成2.87亿美元D1轮融资押注口服GLP-1，箕星冲向下一代减重药

Core Viewpoint - The article discusses significant developments in the GLP-1 receptor agonist market, highlighting recent financing events and advancements in drug development aimed at obesity and type 2 diabetes treatment [4][6]. Group 1: Company Developments - On January 20, 2026, Gilead Sciences announced the selection of a new generation of monthly subcutaneous GLP-1R/GIPR/GCGR triple receptor agonists [4]. - On January 22, 2026, Jixing Pharmaceuticals completed a $287 million Series D financing round, focusing on the clinical development of its oral small molecule GLP-1 receptor agonist CX11 for obesity, overweight, and type 2 diabetes [4]. - The funds raised will support ongoing Phase II clinical trials for obesity and type 2 diabetes in the U.S. and prepare for subsequent Phase III trials [4]. Group 2: Product Insights - CX11 is an oral small molecule GLP-1 receptor agonist designed to provide a more convenient alternative to current injectable GLP-1 therapies [6]. - In December 2024, Jixing Pharmaceuticals acquired global rights (excluding China) to the CX11 project from Wenta Pharmaceutical, integrating it into their core pipeline [6]. - The CEO of Jixing Pharmaceuticals stated that this financing marks a significant milestone for the company, accelerating innovation in cardiovascular metabolic disease drug development and indicating a new phase of global growth [6]. Group 3: Investment Landscape - The financing round attracted notable international biopharmaceutical investors, including RTW Investments and Hengdian Capital, along with new investors such as SR One, TCGX, RA Capital Management, and others [6]. - This reflects a sustained interest from top-tier investors in the oral GLP-1 space, indicating confidence in the potential of these therapies [6].